Related by context. All words. (Click for frequent words.) 66 Median progression 64 resected pancreatic cancer 64 postoperative chemotherapy 64 FOLFOX4 64 locoregional recurrence 64 Folfox 64 oral Hycamtin 63 Free Survival PFS 63 biochemical relapse 63 squamous histology 63 radiochemotherapy 63 complete cytogenetic response 62 oblimersen 62 cisplatin gemcitabine 62 plus dexamethasone 61 demonstrated antitumor activity 61 Platinol ® cisplatin 61 locoregional disease 61 estramustine 61 metastatic castration resistant 60 stage IIIb IV 60 clodronate 60 concurrent chemoradiation 60 plus prednisone 60 cisplatin vinorelbine 60 Hormone Refractory Prostate Cancer 60 pegylated liposomal doxorubicin 60 biochemical recurrence 60 pancreatic adenocarcinoma 60 neoadjuvant therapy 60 Median PFS 60 Secondary endpoints included 60 CR nPR 60 locoregional 59 debulking surgery 59 cytoreductive surgery 59 progression TTP 59 angiographic restenosis 59 Operative mortality 59 NMIBC 59 gemcitabine chemotherapy 59 free survival PFS 59 % CI #.#-#.# [003] 59 carboplatin chemotherapy 59 standard chemotherapy regimen 59 synthase TS 59 low dose cytarabine 59 cytoreduction 59 adjuvant cisplatin 59 recurrent metastatic 59 BEXXAR Therapeutic Regimen 59 viral titers 59 oral clodronate 59 FOLFIRI 58 peritoneal carcinomatosis 58 PSA nadir 58 median PFS 58 nodular partial response 58 preoperative chemotherapy 58 5-fluorouracil/leucovorin 58 CR CRu 58 echocardiographic parameters 58 #Gy 58 CCyR 58 FOLFOX4 alone 58 binary restenosis 58 neurologic progression 58 baseline LDH 58 pCR 58 gemcitabine carboplatin 58 colorectal metastases 58 chemoradiotherapy 58 BEACOPP 58 Inhaled nitric oxide 58 distant metastasis 57 neoadjuvant radiation 57 postoperative mortality 57 nonsquamous 57 Radical prostatectomy 57 PROSTVAC VF 57 irinotecan cisplatin 57 paclitaxel carboplatin 57 neointimal 57 p = NS 57 perioperative mortality 57 infliximab monotherapy 57 adjuvant radiation 57 PSADT 57 Secondary endpoints include 57 Stage IIIb 57 perioperative morbidity 57 pT3 57 mutated KRAS 57 epirubicin cyclophosphamide 57 nodal metastasis 57 remission CR 57 cyclophosphamide chemotherapy 57 VcMP 57 malignant neoplasm 57 Kaplan Meier analysis 57 care regimens CCR 57 FOLFIRI alone 57 underwent resection 57 lumbar spine BMD 57 cisplatin chemotherapy 57 tenecteplase 57 adenoma recurrence 56 tumor progression TTP 56 primary patency 56 PASI scores 56 low dose Iluvien 56 % Confidence Interval 56 liver metastasis 56 imatinib therapy 56 Doxil ® 56 Hazard Ratio HR 56 cEVR 56 doxorubicin docetaxel 56 cytogenetic response 56 recurrent Hodgkin 56 nonmetastatic 56 recurrent glioblastoma 56 kidney allograft 56 disease progression TTP 56 Response Evaluation Criteria 56 recurrent GBM patients 56 placebo dexamethasone 56 metastatic gastric 56 oxycodone CR 56 MACCE 56 prostate cancer CRPC 56 completely resected 56 node dissection 56 postoperative radiotherapy 56 bone metastasis 56 HBeAg seroconversion 56 severe neutropenia 56 KRAS wild 55 antiangiogenic agents 55 cancer mCRC 55 5-FU/LV 55 hip BMD 55 % CI #.#-#.# [007] 55 extrapleural pneumonectomy 55 death reinfarction 55 pulmonary metastasis 55 lumen diameter 55 iniparib BSI 55 intra arterial chemotherapy 55 Adjuvant chemotherapy 55 serum clusterin levels 55 stage IIIb 55 T2 lesions 55 cellularity 55 confirmed CCyR 55 Halaven 55 interferon ribavirin 55 nodal metastases 55 mL/min/#.# m 2 55 paclitaxel poliglumex 55 symptomatic intracerebral hemorrhage 55 RECIST Response Evaluation Criteria 55 localized renal 55 prospectively stratified 55 graft dysfunction 55 Kaplan Meier method 55 clinically localized prostate 55 HER2 expression 55 intra abdominal abscess 55 R0 resection 55 satraplatin Phase 55 preintervention 55 previously untreated follicular 55 pulmonary artery banding 55 Partial Responses 55 refractory colorectal cancer 55 median survivals 55 cisplatin resistant 55 axitinib 55 recurrent myocardial infarction 55 transplantation HCT 55 5FU 55 malignancy HCM 55 infarct size 55 unresectable stage 55 randomized Phase 2b 55 radiographic progression 54 Stage IIB 54 annualized relapse 54 EGFR mutation positive 54 Neoadjuvant 54 glufosfamide 54 TLUS 54 distant metastases 54 mg qd 54 follicular Non Hodgkin 54 metastatic renal 54 systolic function 54 recurrent VTE 54 ALND 54 SUVmax 54 stem cell engraftment 54 CI #.#-#.# [001] 54 mRCC 54 zoledronic acid 54 -#.# log# 54 antitumor effect 54 endoscopic ultrasonography 54 adjuvant hormonal therapy 54 response pCR 54 EGFR TKI 54 Partial Response 54 randomized multicenter Phase III 54 Circulating tumor cells 54 chemoradiation 54 QTcF 54 oncologic outcomes 54 -#.# mg dL [001] 54 pulmonary exacerbations 54 myocardial viability 54 gp# vaccine 54 ratio ICER 54 neutrophil counts 54 perioperative complications 54 pelvic lymphadenectomy 54 histological subtype 54 Adjuvant therapy 54 Hazard Ratio = 54 Coronary Artery Bypass Graft 54 FOLFOX 54 temsirolimus 54 underwent surgical resection 54 Kaplan Meier curve 54 Kloski noted 54 Follicular Lymphoma 54 androgen suppression 54 pulmonary exacerbation 54 Solid Tumors RECIST 54 anaplastic astrocytomas 54 allogeneic HSCT 54 neoadjuvant treatment 54 following antiestrogen therapy 54 P = .# 53 lymph node metastasis 53 custirsen 53 vincristine doxorubicin 53 Metastatic colorectal cancer 53 LVEF 53 Secondary endpoints 53 Lung transplantation 53 leukocyte count 53 ER CHOP 53 percutaneous biopsy 53 T1a 53 cTnI 53 preoperative PSA 53 metastatic renal cell carcinoma 53 paclitaxel cisplatin 53 #.#ng/ml 53 chronic myeloid 53 androgen deprivation 53 abiraterone acetate 53 fittest Bucher 53 mTOR inhibition 53 acute GVHD 53 standard chemotherapy regimens 53 neuropathy sensory 53 stage IIIB IV 53 atypical lobular hyperplasia 53 neurocognitive function 53 prolongs survival 53 WBRT alone 53 extracapsular extension 53 neoadjuvant chemotherapy 53 renal allograft 53 visceral metastases 53 minimally symptomatic 53 colorectal cancer liver metastases 53 radical retropubic prostatectomy 53 Oral Cavity Soft Palate 53 cabazitaxel 53 surgical debulking 53 prognostic variables 53 FOLFIRINOX 53 KRAS mutant tumors 53 lung metastasis 53 postintervention 53 small lymphocytic lymphoma 53 castrate resistant 53 triglyceride concentrations 53 EGFR mutant 53 plasma uric acid 53 operable breast cancer 53 residual stenosis 53 CIN3 53 T1c 53 specific alkaline phosphatase 53 reintervention 53 induce remission 53 invasive lobular 53 patients evaluable 53 fibrinolysis 53 EDSS scores 53 Index CDAI 53 non squamous histology 53 Chronic lymphocytic leukemia CLL 53 nadroparin 52 mean ± SEM 52 cystectomy 52 mitoxantrone 52 ACR# responses 52 Crohn Disease Activity 52 relapsed ovarian cancer 52 chemoresistant 52 neurologic outcomes 52 VEGF inhibition 52 TroVax ® 52 chemotherapy docetaxel 52 mCRPC 52 anti angiogenic agents 52 virologic response 52 RECIST criteria 52 hematopoietic cell 52 % CI #.#-#.# [001] 52 Rectal cancer 52 pulmonary dysfunction 52 glomerular filtration 52 CRp 52 HSCT 52 irinotecan chemotherapy 52 ixabepilone 52 refractory acute myeloid 52 antithymocyte globulin 52 HNSCC 52 dacarbazine chemotherapy 52 serum prostate 52 multiple myeloma MM 52 clinicopathological features 52 decitabine 52 inhibited tumor 52 multivariable analysis 52 chronic periodontitis 52 mg/m2 dose 52 tumor resection 52 curative resection 52 VIDAZA azacitidine 52 alanine aminotransferase ALT 52 log# copies mL 52 peritoneal cancer 52 Randomized clinical trials 52 androgen ablation 52 IV NSCLC 52 perioperatively 52 hENT1 52 Kaplan Meier 52 colorectal polyp 52 cardiac dysfunction 52 relapsed SCLC 52 mCRC patients 52 femoral neck BMD 52 plus OBT 52 etoposide 52 Acute myelogenous leukemia 52 neoadjuvant 52 Annualized ROE 52 KRAS status 51 ispinesib administered 51 p = .# [001] 51 thrombotic complications 51 hepatic fibrosis 51 % CI #.#-#.# [008] 51 ADVEXIN therapy 51 EDSS score 51 Median survival 51 prostate cancer CaP 51 Kaplan Meier estimates 51 lymph node dissection 51 Prostate Cancer Recurrence 51 sustained virologic response 51 histologic 51 polyp recurrence 51 stent binary restenosis 51 CMV disease 51 anti leukemic 51 arterial thickening 51 μg L 51 milatuzumab 51 Avastin Tarceva 51 mIU ml 51 serum HBV DNA 51 clinically evaluable patients 51 methotrexate monotherapy 51 tracer uptake 51 substantially improves treatability 51 antithrombotic therapy 51 liver transplant recipients 51 hyperoxia 51 PV module efficiencies 51 prognostic indicator 51 adenoma detection 51 mutated K ras 51 lymph node involvement 51 adjuvant therapy 51 Medcath NASDAQ MDTH 51 Major Adverse Cardiac 51 relapsed ALL 51 KRAS mutation 51 EGFR expressing mCRC 51 bacterial bloodstream infections 51 Shark cartilage 51 topotecan 51 mg kg dose 51 radioiodine therapy 51 pancreatic islet cell 51 p = #.# [004] 51 evaluable 51 liver metastases 51 preterm newborns 51 Scale EDSS 51 reoperation 51 p# biomarkers 51 multivessel coronary artery 51 immunosuppressive regimens 51 allogeneic SCT 51 Improved Progression 51 rituximab refractory 51 modified RECIST criteria 51 posttransplant 51 ADVEXIN efficacy 51 metastatic lung cancer 51 taxotere 51 gastric cardia 51 coronary revascularization 50 undetectable HBV DNA 50 HRPC 50 -#.# log# copies mL 50 chemosensitivity 50 chemo radiotherapy 50 clonogenic 50 cytogenic 50 non mutated KRAS 50 rapid virological response 50 MELD scores 50 tumor histology 50 glycated hemoglobin HbA1c 50 HbA1C levels 50 intensity allogeneic stem 50 tesmilifene 50 relapsed AML 50 TPV r 50 creatine kinase MB 50 cardiac allograft vasculopathy 50 hepatic veins 50 resected tumors 50 IV malignant melanoma 50 myocardial function 50 relapsed GBM 50 HIV HCV coinfected 50 SVR# 50 left ventricular LV 50 stage IIIA 50 DAS# remission 50 Palifosfamide delivers 50 Bystander CPR 50 BMPR2 50 pooled comparator 50 refractory metastatic 50 Virologic 50 mismatched bone marrow 50 p# Shc 50 tertile 50 SCr 50 metastatic prostate 50 serum creatinine levels 50 sustained virological response 50 elevated LDH 50 bortezomib 50 incurable prostate 50 Paraplatin ® carboplatin 50 Postoperative 50 TMEM density 50 axillary dissection 50 haematopoietic 50 Platelet counts 50 ulcer healing 50 FLT3 ITD 50 sUA levels 50 Kaplan Meier curves 50 tumor shrinkage 50 HOMA IR 50 pancreatic resection 50 chemoresistance 50 heavily pretreated 50 prognostic factor 50 rFVIII 50 lamivudine monotherapy 50 Prognostic factors 50 #.#mg/dL 50 gemcitabine 50 breast conserving lumpectomy 50 heavily pretreated patients 50 preoperative staging 50 Breslow thickness 50 Acute myeloid leukemia 50 specific antigen PSA 50 univariate analysis 50 chemotherapeutic regimens 50 baseline FEV 50 virological suppression 50 undetectable PSA 50 cranial irradiation 49 PCA3 scores 49 bevacizumab Avastin Genentech 49 survivin expression 49 nephron sparing surgery 49 aneurysm sac 49 myeloablative 49 Autologous stem cell 49 NNRTI resistance 49 lung fibrosis 49 VIDAZA 49 refractory acute lymphoblastic 49 ciclosporin 49 normothermia 49 prognostic significance 49 Kaplan Meier estimate 49 pelvic radiotherapy 49 immunosuppressive regimen 49 transgene expression 49 carotid artery thickness 49 GOVERNMENT MEETINGS 49 Leydig cell 49 RECIST 49 ocular melanoma 49 Lorianne Masuoka MD 49 Clot busting 49 Diastolic 49 neurodevelopmental impairment 49 μg liter 49 CK MB 49 tumor regressions 49 lowest tertile 49 angiogenesis inhibition 49 carboplatin 49 nuclease degradation 49 permanently discontinue Vectibix 49 tumor recurrence 49 univariate 49 imatinib 49 pmol L 49 immunosuppression therapy 49 mcg albinterferon alfa 2b 49 esophageal tumors 49 underwent liver transplantation 49 nmol l 49 trough FEV1 49 Disorienting episodes added 49 tumor regression 49 clinicopathological 49 graft patency 49 highest tertile 49 adjuvant chemotherapy 49 serum IGF 49 mmHg systolic 49 Baseline characteristics 49 CYP#D# genotype 49 noncardiovascular mortality 49 mmHg p = 49 durable remissions 49 DAS# scores 49 Available Seat Kilometres ASKs 49 #.#-#.# [011] 49 auto allo 49 tPSA 48 mm ³ 48 lymphocyte count 48 rhabdoid 48 diffuse intrinsic pontine glioma 48 serum transaminases 48 Androgen Deprivation 48 ERCC1 48 eribulin 48 LAB GHRH 48 colonic polyps 48 severe periodontitis 48 synovial cell 48 GvHD 48 seminoma 48 multivariable Cox 48 Prostate specific antigen 48 anthracycline containing 48 antioxidant supplementation 48 KRAS mutation status 48 serum testosterone 48 5 HT2C receptor 48 posttreatment 48 metastatic kidney 48 contractile muscle 48 Å -1 48 CPAP adherence 48 oncological outcomes 48 Recurrence 48 thymic carcinoma 48 seropositivity 48 HbA1C 48 baseline A1C 48 autologous transplants 48 KRAS mutant 48 GISTs 48 recanalization 48 BRCA mutation carriers 48 anti inflammatory cytokine 48 adjuvant therapies 48 TNFerade 48 irradiated mice 48 pg ml 48 NSCL cancer 48 hemodialysis patients 48 invasive fungal 48 cintredekin besudotox 48 GVAX 48 physis 48 pg mL 48 A1c levels 48 median CD4 48 #.#mmol L [001] 48 Scale EDSS score 48 MIC# [001] 48 % CI #.#-#.# [006] 48 detecting precancerous 48 crossclamp 48 Capacity FVC 48 serum testosterone levels 48 virological response 48 Homocysteine levels 48 Univariate analysis 48 target lesion revascularization 48 trochanter 48 metabolic syndrome clustering 48 AUA Symptom Score 48 ng dL 48 RBC transfusions 48 Kalantar Zadeh 48 acute myelogenous 48 transplanted livers 48 VT VF 47 sentinel lymph node biopsy 47 IBDQ 47 immunosuppressive medication 47 serum magnesium 47 parkinsonian symptoms 47 preoperative intraoperative 47 Firm NorCal 47 viral reactivation 47 Montgomery Asberg Depression 47 nmol liter 47 spontaneous regression 47 myelogenous leukemia 47 Insulin sensitivity 47 ALSFRS R 47 catheter colonization 47 granulocyte 47 lung colon rectum 47 Graft Versus Host 47 mutant p# 47 relapsed follicular 47 ependymoma 47 pemetrexed 47 Vectibix monotherapy 47 colon rectum breast 47 ventricular ejection fraction 47 alveolar rhabdomyosarcoma 47 XL# administered orally 47 spontaneous circulation ROSC 47 spontaneous preterm delivery 47 neurodevelopmental outcome 47 virologic responses 47 C diff infections 47 VIDAZA ® 47 inhaled tobramycin 47 gefitinib 47 estimated glomerular filtration 47 Spokeswoman Amy Cianciaruso 47 circulating lymphocytes 47 mL sec 47 proteins HSP 47 bronchopulmonary dysplasia BPD 47 tertiles 47 Surfactant gross 47 Bcl xL 47 TRAIL induced apoptosis 47 procollagen 47 hormone receptor status 47 micronuclei 47 recurrent wheezing 47 antibody mediated 47 limb salvage 47 prognostic indicators 47 fullyear outturn represents 47 cobalt chromium alloy 47 bears Servheen 47 Housing Starts Plunge 47 CVD mortality 47 estrogen receptor negative 46 erlotinib 46 Complication rates 46 total hip arthroplasties 46 TOTAL REV 46 attain statistical significance 46 clopidogrel therapy 46 Stomach stapling 46 ferroportin levels 46 Colorectal cancer incidence 46 QRS interval 46 revascularisation 46 ANCOVA 46 Hemoglobin A1c 46 gastric atrophy 46 EGFR mutation status 46 Lower Limb 46 dopamine neuron 46 poorer prognosis 46 Randomized trials 46 IFN alpha 2a 46 alveolar bone loss 46 hVISA patients 46 waist girth 46 cecal intubation 46 Nondurable goods orders 46 decompressions 46 AMPYRA doses 46 CMV reactivation 46 sero positive 46 Waldenstrom macroglobulinemia 46 palliation 46 contrast barium enema 46 localized prostate 46 aware NAT Firewall 46 blood clots thrombosis 46 confidence intervals CIs 46 bowel resection 46 was#.# 46 MCF7 cells 46 interquartile range 46 RBC transfusion 46 undergoing liver transplantation 46 Retail postpaid churn 46 cells mcL 46 advanced individualized immunotherapies 46 urgent revascularization 46 humoral immunity 46 virologic failure 46 CD# upregulation 46 BPH Symptom Score 46 curability 46 CD4 + cell 46 intravenous CK # 46 radical prostatectomy 45 BR.# study 45 skin sparing mastectomies 45 Ex Autos 45 logistic regression analysis 45 p = #.# [002] 45 CD# + [001] 45 seroprotection 45 circulating endothelial 45 renal carcinoma 45 Caloric restriction 45 noncarriers 45 survival 45 surrogate endpoint 45 Natalie Portman ballet 45 cancerdefine 45 immune reconstitution 45 CI = 45 unformulated vaccine 45 cisplatin 45 mean baseline A1C 45 reperfusion 45 EGFR inhibitors 45 hours postdose 45 Implantable cardioverter defibrillators ICDs 45 mean baseline HbA1c 45 Oesophageal cancer 45 Pain Intensity 45 enzymatic modification 45 Helicopters whirred overhead 45 morbidity mortality 45 exogenous insulin 45 IPSS 45 folic acid takers 45 hormonally responsive 45 KRAS mutations 45 chronic HCV genotype 45 CK # plasma 45 treatment naļve 45 fluorescence intensity 45 patency 45 de ath 45 hedonically sic 45 Univariate 45 odds ratios ORs 45 tumor subtype 45 lowering blood glucose 45 from#.# [001] 45 indolent lymphomas 44 underwent CABG 44 noninfected 44 SEER registries 44 highest quintile 44 nephron sparing 44 Garcia Manero 44 β cell 44 childhood acute lymphoblastic 44 Merit FOM 44 refracture 44 ± SEM 44 breast cancer recurrence 44 postmenopausal breast cancer 44 furthers procreation essential 44 Wilms tumors 44 EGFR mutation 44 YonY 44 x 5cm 44 nocturnal hypoglycaemia 44 PBDE chemicals 44 cancellous 44 ® emtricitabine 44 ovulatory cycles 44 artery reclogging 44 zibotentan 44 malignant brain 44 neoadjuvant chemoradiotherapy 44 megakaryocytes 44 Vectibix 44 polymorphonuclear leukocytes 44 AML acute myeloid 44 surgical resection 44 mammary tumors 44 glomerular filtration rate 44 Wang Ziqi director 44 carotid plaques 44 stem progenitor cells 44 urethral obstruction 44 abiraterone 44 male hormones androgens 44 hematologic malignancy 44 patients undergoing chemotherapy 44 Hospitalizations 44 Harshness NVH 44 suppress viral replication 44 Average Stockholders Equity 44 untreated mice 44 lymphoid cancers 44 serum CRP 44 logistic regression analyzes 44 autologous transplantation 44 revascularization 44 HIV tropism 44 prognostic marker 44 ipilimumab 44 Unemployment Holds Steady 44 habitat poaching 44 leukaemic 44 q#d 43 refractory ALCL 43 Kaplan Meier survival 43 Wireline EBITDA 43 intraperitoneal therapy 43 volumetric efficiency 43 hormone refractory 43 DNA encased MWCNTs 43 Expanded Disability Status 43 prior chemotherapy regimens 43 Mainline RPMs 43 Jhdm2a 43 prognostically 43 renal transplantation 43 abdominal subcutaneous fat 43 Charlson comorbidity index 43 #.#mln rub [004] 43 Estrogen receptor positive 43 precancerous colon growths 43 corneal neovascularization 43 moderate immunologic 43 Universal Sanctum 43 bronchopulmonary dysplasia 43 gamma globin 43 #bps qoq [001] 43 Genetic variation 43 sickest colon cancer 43 X ULN 43 perinatal asphyxia 43 leukemic stem cells 43 K ras gene 43 sepal 43 Adjusted Ebitda 43 Hb A1c 43 to#.# [003] 43 QALY gained 43 horror experienceA student 43 shrink cancerous tumors 43 #.#mln rub [005] 43 baseline CD4 43 TYPE Front 43 acute lymphoblastic 43 tumor progression 43 Leukemia lymphoma 43 Repeatability 43 vaccine Oncophage 43 chronic HBV 43 Stroke REGARDS study 43 siblings girls Ebuka 43 conspicuity 43 DEET absorption 43 neurodevelopmental outcomes 43 mammary tumor formation 43 dopaminergic neuron 43 ECD kidneys 43 Womacks Adjusted EBITDA 43 EGFR expression 43 NHANES III 43 melanocyte 43 Jobless Claims Climb 43 preeclamptic 43 nonischemic cardiomyopathy 43 HER2 homodimer levels 42 myocardial infarctions MIs 42 telomere lengths 42 recurrence 42 Unemployment Dips 42 #mln rub [001] 42 fractional anisotropy 42 stromal tissue 42 prostate tumor 42 vandetanib #mg 42 Nominal incomes 42 muscular dystrophy cystic fibrosis 42 rubber spatula gently 42 aircrew situational awareness 42 #Y yield 42 Skydive survivor 42 = #.#f 42 persistency mortality 42 mmol liter 42 transplanted islets 42 #.#bn rub [003] 42 interquartile range IQR 42 steam pasteurized smokeless 42 type KRAS 42 phenotypic expression 42 courtesies seamanship skills 42 genital ulcer 42 Main Outcome Measures 42 Wafer shipments 42 Liveauctioneers.com bidders represent 42 #R #R #R [002] 42 anatomically shaped 42 Locust Horde nightmarish 42 apparent diffusion coefficient 42 REIT Taxable 42 nmol L. 42 interbody 42 Eliezer Zomer Ph.D. 42 Relative Strength Ratio XLY 42 Unemployment Rate Dips 42 Unemployment Rate Holds Steady 42 EUROCARE 42 inhibin B 42 drank pomegranate juice 42 MiG Element 42 HH GLI 42 Churn Rate 42 Xten softphones 42 malignant phenotype 42 prognostic factors 42 mutant KRAS 42 aneuploid 42 #.#mln rub [006] 42 non Hodgkin Lymphoma 41 CFVR 41 Consensus +#.# 41 IDH2 41 uninterrupted chest compressions 41 AJCC 41 Gleevac 41 kidney transplant recipients 41 from#.# [002] 41 Index RMPI 41 n = 41 1ß 41 Kaklamani 41 EXISTING HOME SALES 41 nSYD# * [001] 41 asymptomatic PAD 41 Seasonally unadjusted 41 achieving sustained virologic 41 cells/mm3 41 ±